Citation Impact
Citing Papers
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
2012 Standout
The Ensembl Variant Effect Predictor
2016 Standout
Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma
2018
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Advances in using PARP inhibitors to treat cancer
2012
Nasopharyngeal carcinoma
2019 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Differentiation of Malignant Thrombus from Bland Thrombus of the Portal Vein in Patients with Hepatocellular Carcinoma: Application of Diffusion-weighted MR Imaging
2009
PARP Inhibitor Treatment in Ovarian and Breast Cancer
2011
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review
2011
Cancer Genome Landscapes
2013 StandoutScience
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Works of Long Sun being referenced
Positron emission tomography/computer tomography in guidance of extrahepatic hepatocellular carcinoma metastasis management
2007
Highly metabolic thrombus of the portal vein: 18F fl uorodeoxyglucose positron emission tomography/computer tomography demonstration and clinical signifi cance in hepatocellular carcinoma
2008
[Serial (18)F-FDG PET-CT imaging during radiotherapy for nasopharyngeal carcinoma: a prospective clinical study].
2012
First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
2011